SeaStar Medical (ICU) Holding reports setting a new monthly enrollment record with 10 critically ill acute kidney injury patients added to the NEUTRALIZE-AKI pivotal trial during the past month, bringing total enrollment to 56. This trial is evaluating the safety and efficacy of the Company’s proprietary therapeutic Selective Cytopheretic Device in adults with AKI in the intensive care unit receiving continuous renal replacement therapy.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICU:
- SeaStar Medical adds second hospital customer for QUELIMMUNE
- SeaStar Medical announces economic analysis data on QUELIMMUNE device
- SeaStar Medical announces Stanford Medicine is cleared to enroll subjects
- SeaStar Medical to distribute QUELIMMUNE directly to hospital customers
- SeaStar announces enrollment in NEURTALIZE-AKI trial passes halfway point